• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer

    4/9/24 4:05:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ILMN alert in real time by email

    Joydeep Goswami to serve as advisor through June 30

    Illumina reaffirms Q1 2024 and full-year 2024 financial guidance

    SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments.

    Ankur Dhingra, who will become Illumina's Chief Financial Officer on April 15.

    Ankur Dhingra is joining Illumina as Chief Financial Officer (CFO), leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics Inc. (NASDAQ:SMMT), and prior to that was CFO of CAREDx, Inc. Dhingra spent more than 18 years at Agilent Technologies, most recently as VP, Investor Relations. Before that, he held various finance leadership roles with progressively increasing responsibility, including multiple business unit CFO roles. He brings experience in developing and executing growth and margin improvement strategies, delivering P&L commitments, and driving businesses toward increasing levels of performance. Dhingra has a demonstrated record of success in executing and influencing growth-oriented business strategies, as well as managing global finance and accounting teams. He is a Chartered Accountant and member of The Institute of Chartered Accountants of India.

    Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

    "I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms. Both are deeply committed to serving our customers and helping Illumina grow."

    Dhingra and Wedel are both relocating to San Diego. They succeed Goswami, who held both the CFO and Chief Strategy and Corporate Development Officer roles since early 2023. Goswami joined Illumina in 2019 to lead strategy and corporate development. He will continue as an advisor to the company starting April 15 and through June 30. He departs the organization on July 1.

    "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions," said Thaysen. "Joydeep will continue with us for several weeks to support a smooth leadership transition."

    The company has reaffirmed its guidance for the first quarter 2024 and full-year 2024, as announced during its fourth quarter 2023 earnings call on February 8, 2024.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    IR@illumina.com

    Media:

    David McAlpine

    347-327-1336

    PR@illumina.com

    Jakob Wedel, who will become Illumina's Chief Strategy and Corporate Development Officer on April 15.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-ankur-dhingra-chief-financial-officer-jakob-wedel-chief-strategy-and-corporate-development-officer-302112206.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN
    $SMMT

    CompanyDatePrice TargetRatingAnalyst
    Illumina Inc.
    $ILMN
    6/26/2026$185.00Mkt Perform
    Bernstein
    Illumina Inc.
    $ILMN
    6/10/2026$185.00Neutral → Overweight
    Analyst
    Summit Therapeutics Inc.
    $SMMT
    5/22/2026Buy → Neutral
    H.C. Wainwright
    Illumina Inc.
    $ILMN
    5/15/2026$170.00Outperform
    RBC Capital Mkts
    Illumina Inc.
    $ILMN
    5/14/2026$155.00Neutral → Outperform
    Daiwa Securities
    Summit Therapeutics Inc.
    $SMMT
    4/8/2026$45.00Buy
    Stifel
    Summit Therapeutics Inc.
    $SMMT
    3/16/2026$15.00Buy → Hold
    Jefferies
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $ILMN
    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

    Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi study is evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with endot

    7/22/26 6:30:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina expands Billion Cell Atlas program with new AI drug developers

    Partners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and

    7/16/26 12:00:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

    Conference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of lif

    7/16/26 8:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein resumed coverage on Illumina with a new price target

    Bernstein resumed coverage of Illumina with a rating of Mkt Perform and set a new price target of $185.00

    6/26/26 9:21:34 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina upgraded by Analyst with a new price target

    Analyst upgraded Illumina from Neutral to Overweight and set a new price target of $185.00

    6/10/26 8:16:12 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Summit Therapeutics from Buy to Neutral

    5/22/26 8:27:33 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:25:34 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:22:10 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/25/26 9:41:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    7/22/26 7:10:49 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/26 9:08:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    6/12/26 4:11:17 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 2:35:11 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 12:28:50 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/4/26 6:08:26 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik

    7/9/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare

    6/23/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ILMN
    $SMMT
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

    Conference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of lif

    7/16/26 8:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we

    7/9/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial Results Simultaneous Publication of Latest Ivonescimab HARMONi-6 Results in The Lancet Summit Conference Call to Be Held at 7:00 a.m. ET on Monday, June 1, 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducte

    5/31/26 9:06:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ILMN
    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care